57.61 USD
-0.34 (-0.59%)
At close: Feb 3, 2026
57.55 USD
-0.06 (-0.1%)
After Hours: 2/3/2026, 8:02:14 PM
BMRN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. BMRN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. BMRN may be a bit undervalued, certainly considering the very reasonable score on growth These ratings could make BMRN a good candidate for value and quality investing.
1. Profitability
1.1 Basic Checks
- In the past year BMRN was profitable.
- BMRN had a positive operating cash flow in the past year.
- Of the past 5 years BMRN 4 years were profitable.
- In the past 5 years BMRN always reported a positive cash flow from operatings.
1.2 Ratios
- BMRN has a Return On Assets of 6.83%. This is amongst the best in the industry. BMRN outperforms 92.75% of its industry peers.
- The Return On Equity of BMRN (8.59%) is better than 92.18% of its industry peers.
- BMRN has a better Return On Invested Capital (7.69%) than 94.08% of its industry peers.
- BMRN had an Average Return On Invested Capital over the past 3 years of 3.73%. This is significantly below the industry average of 18.09%.
- The 3 year average ROIC (3.73%) for BMRN is below the current ROIC(7.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROIC | 7.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 16.82%, BMRN belongs to the best of the industry, outperforming 92.75% of the companies in the same industry.
- The Operating Margin of BMRN (20.21%) is better than 94.66% of its industry peers.
- The Gross Margin of BMRN (81.32%) is better than 85.31% of its industry peers.
- BMRN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BMRN is destroying value.
- The number of shares outstanding for BMRN has been increased compared to 1 year ago.
- The number of shares outstanding for BMRN has been increased compared to 5 years ago.
- The debt/assets ratio for BMRN has been reduced compared to a year ago.
2.2 Solvency
- BMRN has an Altman-Z score of 5.48. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
- BMRN has a better Altman-Z score (5.48) than 73.66% of its industry peers.
- BMRN has a debt to FCF ratio of 0.72. This is a very positive value and a sign of high solvency as it would only need 0.72 years to pay back of all of its debts.
- BMRN has a better Debt to FCF ratio (0.72) than 94.47% of its industry peers.
- A Debt/Equity ratio of 0.10 indicates that BMRN is not too dependend on debt financing.
- BMRN's Debt to Equity ratio of 0.10 is on the low side compared to the rest of the industry. BMRN is outperformed by 62.40% of its industry peers.
- Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Altman-Z | 5.48 |
ROIC/WACC0.91
WACC8.46%
2.3 Liquidity
- BMRN has a Current Ratio of 4.83. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
- BMRN has a Current ratio (4.83) which is in line with its industry peers.
- A Quick Ratio of 3.10 indicates that BMRN has no problem at all paying its short term obligations.
- With a Quick ratio value of 3.10, BMRN is not doing good in the industry: 60.88% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 52.00% over the past year.
- Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 12.39% in the last year.
- Measured over the past years, BMRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.86% on average per year.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
3.2 Future
- The Earnings Per Share is expected to grow by 28.19% on average over the next years. This is a very strong growth
- BMRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.22% yearly.
EPS Next Y28.21%
EPS Next 2Y44.96%
EPS Next 3Y35.45%
EPS Next 5Y28.19%
Revenue Next Year12.62%
Revenue Next 2Y11.16%
Revenue Next 3Y10.75%
Revenue Next 5Y7.22%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 21.66, BMRN is valued on the expensive side.
- Compared to the rest of the industry, the Price/Earnings ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 94.66% of the companies listed in the same industry.
- BMRN is valuated rather cheaply when we compare the Price/Earnings ratio to 28.18, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 12.41, the valuation of BMRN can be described as correct.
- Based on the Price/Forward Earnings ratio, BMRN is valued cheaper than 97.71% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of BMRN to the average of the S&P500 Index (25.51), we can say BMRN is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.66 | ||
| Fwd PE | 12.41 |
4.2 Price Multiples
- BMRN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BMRN is cheaper than 95.23% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, BMRN is valued cheaper than 97.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.4 | ||
| EV/EBITDA | 14.16 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- BMRN has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as BMRN's earnings are expected to grow with 35.45% in the coming years.
PEG (NY)0.77
PEG (5Y)N/A
EPS Next 2Y44.96%
EPS Next 3Y35.45%
5. Dividend
5.1 Amount
- BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
57.61
-0.34 (-0.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-27 2025-10-27/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners97.82%
Inst Owner Change-2.77%
Ins Owners0.64%
Ins Owner Change-0.95%
Market Cap11.07B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts81.88
Price Target93.43 (62.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)1.47%
PT rev (3m)-2.38%
EPS NQ rev (1m)-29.03%
EPS NQ rev (3m)-25.47%
EPS NY rev (1m)-5.52%
EPS NY rev (3m)-16.53%
Revenue NQ rev (1m)0.68%
Revenue NQ rev (3m)0.61%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)0.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.66 | ||
| Fwd PE | 12.41 | ||
| P/S | 3.58 | ||
| P/FCF | 13.4 | ||
| P/OCF | 12.11 | ||
| P/B | 1.83 | ||
| P/tB | 1.97 | ||
| EV/EBITDA | 14.16 |
EPS(TTM)2.66
EY4.62%
EPS(NY)4.64
Fwd EY8.06%
FCF(TTM)4.3
FCFY7.46%
OCF(TTM)4.76
OCFY8.26%
SpS16.11
BVpS31.53
TBVpS29.29
PEG (NY)0.77
PEG (5Y)N/A
Graham Number43.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROCE | 9.17% | ||
| ROIC | 7.69% | ||
| ROICexc | 9.82% | ||
| ROICexgc | 10.68% | ||
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% | ||
| FCFM | 26.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Debt/EBITDA | 0.84 | ||
| Cap/Depr | 106.6% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 85.91 | ||
| Cash Conversion | 129.08% | ||
| Profit Quality | 158.68% | ||
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 5.48 |
F-Score8
WACC8.46%
ROIC/WACC0.91
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y28.21%
EPS Next 2Y44.96%
EPS Next 3Y35.45%
EPS Next 5Y28.19%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.62%
Revenue Next 2Y11.16%
Revenue Next 3Y10.75%
Revenue Next 5Y7.22%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.1%
EBIT Next 3Y41.17%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to BMRN.
What is the valuation status for BMRN stock?
ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.
Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 7 / 10.
What is the financial health of BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The financial health rating of BIOMARIN PHARMACEUTICAL INC (BMRN) is 7 / 10.
What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 28.21% in the next year.